Polymorphic markers of the G1639A form of VKORC1 involved in the development of retinal vessel occlusion
- Authors: Moshetova L.K.1, Kaghktsyan S.S.1, Sichev D.A.1, Turkina K.I.1, Grishina E.A.1, Ryzhikova K.A.1, Sozaeva Z.A.1
-
Affiliations:
- Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
- Issue: Vol 9, No 3 (2016)
- Pages: 5-9
- Section: Articles
- URL: https://journals.rcsi.science/ov/article/view/5346
- DOI: https://doi.org/10.17816/OV935-9
- ID: 5346
Cite item
Abstract
Retinal vessel occlusion (RVO) is an eye disease that leads to decreased visual acuity, ultimately resulting in blindness. It is observed in 1%-2% of individuals above the age of 40 years. The etiology of RVO still remains unclear. However, the most widely recognized risk factors include age, hypertension, hyperlipidemia, atherosclerosis, cardiovascular diseases, and diabetes. The number of patients with RVO among the young population has increased in recent years; hence, more attention has been focused on the genetic factors. Polymorphisms in the genes encoding proteins involved in the vitamin K cycle are among the genetic factors that may influence RVO. According to literature, the G1639A polymorphism in the vitamin K epoxide reductase complex subunit 1 (vKoRc1) is a possible risk factor for RVO.
Purpose. To estimate the association between carriers of the G1639A form of vKoRc1 and the development of venous RVO (VRVO) and arterial RVO (ARVO).
Materials and methods. The study included 126 patients aged between 40 and 80 years, mean age 61.5 years. Genotyping for the presence of the G1639A polymorphism of vKoRc1 was performed using polymerase chain reaction, and statistical analysis was performed using the Instat program.
Results. The GG genotype of G1639A was found to be significantly more common in patients with VRVO or ARVO than in those of the control group (VRVO, 42.6%; ARVO, 60%; control group, 32%; p = 0.0449 for VRVO, and p = 0.0925 for ARVO). However, the AA genotype was significantly less common in patients with VRVO or ARVO than in those of the control group (VRVO, 9.8%; ARVO, 6.7%; control group, 28%; p = 0.0238 for VRVO and p = 0.1593 for ARVO, RR 2.015, 95% confidence interval 1.011-4.16).
Conclusions. Our study demonstrates that the GG genotypic form of the G1639A polymorphism of VKORC1 is associated with the development of VRVO and possibly ARVO. However, the AA genotypic form of this polymorphism is not closely associated with the development of VRVO or ARVO.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Larisa K. Moshetova
Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
Author for correspondence.
Email: moshetovalk@yandex.ru
MD, PhD, professor
Russian FederationShushanik S. Kaghktsyan
Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
Email: k.shushan@mail.ru
MD
Russian FederationDmitry A. Sichev
Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
Email: dimasychev@mail.ru
MD, PhD, professor
Russian FederationKseniya I. Turkina
Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
Email: kseniyait@mail.ru
MD, PhD, assistant professor
Russian FederationElena A. Grishina
Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
Email: gelana2010@yandex.ru
PhD
Russian FederationKristina A. Ryzhikova
Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
Email: kriistinkaa@mail.ru
MD, junior researcher
Russian FederationZhannet A. Sozaeva
Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
Email: sozaeva@yandex.ru
laboratory researcher
Russian FederationReferences
- Flammer J, Konieczka K, Bruno R, et al. The eye and the heart. J Eur Heart. 2013;34(17):1270-1278. doi: 10.1093/eurheartj/eht023.
- Lee J, Yoon Y, Kim H, et al. Baseline characteristics and risk factors of retinal vein occlusion. J of Korean Medical Science. 2013;28(1):136-144. doi: 10.3346/jkms.2013.28.1.136.
- Lecumberri J, Balbas C, Villanueva J, Hernandez J. Thrombophilia and vascular risk factors in retinal vein occlusion. J Revistaclinica Espanola. 2013;213(5):229-234. doi: 10.1016/j.rce.2013.01.012.
- Risse F, Frank R, Weinberger A. Thrombophilia in patients with retinal vein occlusion: a retrospective analysis. J Ophthalmologica. 2014;232(1):46-52. doi: 10.1159/000360013.
- Glueck C, Hutchins R, Jurantee J, et al. Thrombophilia and retinal vascular occlusion. J Clinical Ophthalmol. 2012;6:1377-1384. doi: 10.2147/OPTH.S34627.
- Aggarwal R, Mirshra V, Aggarwal S. Oral contraceptive pills: A risk factor for retinal vascular occlusion in in-vitro fertilization patients. J of Human Reproductive Sciences. 2013;6(1):79-81. doi: 10.4103/0974-1208.112389.
- Oldenburg J, Marinova M, Muller-Reible C, Watzka M.
- The vitamin K cycle. J Vitamins and Hormones. 2008;78:36-54. doi: 10.1016/S0083-6729(07)00003-9;2008.
- Oldenburg J, Bevans C, Muller C, Watzka M. Vitamin K epoxide reductase complex subunit 1 of the vitamin K cycle. J Antioxidants and Redox Signaling. 2006;8(3):347-351. doi/abs/10.1089/ars.2006.8.347.
- Тульцева С.Н., Астахов Ю.С. Окклюзии вен сетчатки. — СПб.: Н-Л, 2010. – С. 7–39. [Tul’tseva SN, AstakhovYS. Retinal vein occlusion. Saint Petersburg: N-L; 2010;7-39 (In Russ).]
- Тульцева С.Н. Тромбофилия как фактор риска развития тромбозов центральной вены сетчатки у лиц молодого возраста // Офтальмологические ведомости. – 2008. – Т. 1. – № 1. – С. 46-51. [Tul’tseva SN. Thrombophilia as a risk factor for the thrombosis development of the central retinal vein in young adults. Ophthalmology Journal. 2008;1(1):46-51. (In Russ).]
- Bodin L, Horellou M, Flaujac C, et al. A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J Thrombosis and Haemostasis. 2005;3:1533-5. doi/10.1111/j.1538-7836.2005.01449.
- Weger M, Stein-Brugger I, Wilfried R, et al. Role of the vitamin K epoxide reductase complex subunit I (VKORC1) — 1639G >A gene polymorphism in patients with retinal vein occlusion. J Current Eye Research. 2013;38(12):1278-1282. doi: 10.3109/02713683.2013.
- Ortak H, Sogut E, Demir H, et al. Preductive value of the vitamin K epoxide reductase complex subunit 1 G-1639A and C1173T single nucleotide polymorphisms in retinal vein occlusion. J Clinical and Experimental Ophthalmology. 2012;1-6. doi:10.1111 /j.1442-9071.2012.02780.